HHHaizhong Huo

Haizhong Huo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haizhong Huo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Meng Luo

    Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

    4 shared publications
  • Hongjie Li

    Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China

    3 shared publications
  • Jiayun Lin

    Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China

    3 shared publications
  • Chihao Zhang

    Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China

    2 shared publications
  • Chihao Zhang

    Department of General Surgery Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China

    2 shared publications
  • Chunpeng Pan

    Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Transcriptome Analysis Reveals the Role of Partial Lymphatic Vessel Ligation in Rats with Cirrhotic Portal Hypertension

    by Zhenghao Wu, Guqing Luo, Jinbo Zhao, Qingxun Zhou, Hongjie Li, Chihao Zhang, Guangbo Wu, Qiang Fan, Xiaoliang Qi, Haizhong Huo, et al.

    The liver lymphatic system plays an essential role during the progression of cirrhotic portal hypertension (PHT), featuring significantly enhanced lymphangiogenesis. However, the role of liver lymphatic functional drainage is understudied in cirrhosis. Therefore, this study aimed to investigate the effects of partial lymphatic vessel ligation (PLVL) of the liver on PHT. The rat model was established by common bile duct ligation (BDL), when PLVL was achieved via ligation of the portal and celiac lymph node. The severity of cirrhosis and PHT were evaluated, as well as macrophage infiltration and lymphangiogenesis. Bulk RNA-seq of liver was used to investigate the underlying mechanisms. Datasets of single-cell and bulk RNA-seq were obtained from the GEO database. Human dermal lymphatic endothelial cells (hLECs) were used for in vitro validation. Ligation of lymphatic drainage caused significant deterioration of liver cirrhosis and PHT in BDL rats. Our bulk RNA-seq suggested significant enrichment of vascular remodeling and angiogenesis-related pathways, as well as lipid metabolism-related biological functions in BDL rats after PLVL. Further analysis combined with public datasets identified several endothelial cell-specific upregulated genes in BDL and PLVL rats. LEC-derived upregulated genes were also identified from bulk RNA-seq of LECs isolated from mice liver, which were validated by incubating hLECs in TNF-α, LPS, TGF-β1. In the current study, we provide the first evidence that liver lymphatic drainage blockade aggravates BDL-induced cirrhotic PHT. LEC-associated secretory proteins might play a potential role in PHT progression, when hepatic inflammation and immune response are considered to be the essential regulatory mechanisms.

  • Retraction
    Open Access

    Retraction Note: Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development

    by Hongjuan Chai, Chunpeng Pan, Mingyang Zhang, Haizhong Huo, Haiyan Shan, Jugang Wu

  • Open Access

    Therapeutic potential of formononetin in cirrhotic portal hypertension: modulating hepatic fibrosis, macrophage polarization, and lymphangiogenesis

    by Zhenghao Wu, Guqing Luo, Hongjie Li, Min Chen, Guangbo Wu, Qiang Fan, Chihao Zhang, Jiwei Yu, Jiayun Lin, Jinbo Zhao, et al.

    Introduction: Formononetin regulates intrahepatic fibrogenesis and macrophage polarization to improve portal pressure and liver function in rats with cirrhotic PHT through SMAD3, STAT1, STAT3 and GSK-3β signaling pathways, and modulates lymphangiogenesis through direct action and macrophage polarization-mediated indirect effects. Formononetin has the potential function of treating cirrhotic PHT.Background and aims: Formononetin (FN) has been reported to have anti-fibrotic effects in the kidneys and anti-M1 polarization effects on macrophages. Lymphangiogenesis is closely associated with macrophages, but its role in cirrhosis and portal hypertension (PHT) remains unclear. This study aims to explore the effects of FN on cirrhotic PHT and the disease-related intrahepatic lymphangiogenesis.Methods: In vivo experiments, bile duct ligation (BDL) induced PHT models were conducted in rats, followed by a 4-week FN treatment (50 mg/kg/day) administered via gavage. Hemodynamics, liver fibrosis, infiltration and polarization of intrahepatic macrophages, as well as intrahepatic lymphangiogenesis, were observed. For in vitro experiments, hepatic stellate cells, macrophages and lymphatic endothelial cells were used to observe the multiple effects of FN.Results: FN significantly ameliorated portal pressure in cirrhosis-induced PHT, improved liver function, and reduced liver fibrosis and hepatic stellate cell activation with decreased SMAD3 protein expression. The intrahepatic macrophage infiltration were markedly decreased, and M1-type macrophage polarization was suppressed by FN, accompanied by inhibition of STAT1, STAT3 and GSK-3β signaling pathways. In PHT models, FN reduced VEGF-C and VEGF-D levels in both the liver and blood, inhibiting intrahepatic lymphangiogenesis in portal area. In vitro, high-dose FN significantly inhibited lymphatic endothelial cell proliferation, while the pro-lymphangiogenic effect of conditioned medium from FN-treated M1 macrophages was diminished.Conclusions: FN significantly ameliorates cirrhotic PHT while reducing fibrosis, suppressing macrophage M1 polarization and inhibiting lymphangiogenesis. This may result from its modulation of multiple signaling pathways (SMAD3, STAT1, STAT3 and GSK-3β).


  • Open Access

    A novel noninvasive assessment of portal pressure from computational biofluid mechanics in patients with portal hypertension

    by Lei Zheng, Guangbo Wu, Jiayun Lin, Hongjie Li, Chihao Zhang, Zhifeng Zhao, Min Chen, Zhenghao Wu, Guqing Luo, Qiang Fan, et al.

    To introduce and assess a novel method for portal pressure measurement based on biofluid mechanics in portal hypertensive patients undergoing surgery. The research was a multi-center, retrospective study, conducted on patients who underwent surgery and measurement of free portal pressure (FPP). There were 118 patients included and 21 patients excluded due to the failure or poor results of Doppler ultrasound, and 97 patients were screened. We used patients’ CT images, Doppler ultrasound results of the portal system, blood density and viscosity to reconstruct their portal system and simulate its internal blood flow. According to the patient’s physical property, geometry, and boundary conditions, the Navier–Stokes equations were solved by FLUENT software, and virtual free portal pressure (vFPP) was calculated. Finally, the Bland–Altman Limits of Agreement, intraclass correlation coefficient (ICC), and the Lin’s concordance correlation coefficient were performed to evaluate the numerical correlation between the vFPP and FPP. All patients enrolled in this study underwent the surgery, and the FPP of patients was measured during the surgery, with a mean FPP of 22.8 ± 3.3 mmHg (range: 13–33 mmHg). Meanwhile, according to computational biofluid mechanics, all patients’ vFPP was calculated. Then, we further explored whether there was a close relationship between vFPP and FPP in the whole population. For the analysis of Bland–Altman Limits of Agreement, the mean value of difference was − 0.1569 (95% CI: − 0.4305 to 0.1167); lower limit of agreement: − 2.8176 (95% CI: − 3.2868 to − 2.3484); upper limit of agreement: 2.5038 (95% CI: 2.0346 to 2.9730). The ICC was 0.9215 (95% CI: 0.8848 to 0.9468). Furthermore, the Lin’s concordance correlation coefficient showed a numerical correlation between the vFPP and FPP, which was 0.9205 (95% CI: 0.8840 to 0.9459). All these results confirmed that our vFPP model could provide an accurate prediction of FPP in patients. The vFPP of patients calculated by computational biofluid mechanics was significantly correlated with the FPP of portal hypertensive patients, which would be a novel, non-invasive, and accurate method for the assessment of portal pressure in surgical patients.

  • Retracted
    Open Access

    Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development

    by Hongjuan Chai, Chunpeng Pan, Mingyang Zhang, Haizhong Huo, Haiyan Shan, Jugang Wu

    Background: High expression of SETD1A, a histone methyltransferase that specifically methylates H3K4, acted as a key oncogene in several human cancers. However, the function and underlying molecular mechanism of SETD1A in ovarian cancer (OV) remain markedly unknown. Methods: The expression of SETD1A in OV were detected by Western blot and analyzed online, and the prognosis of STED1A in OV were analyzed online. The protein and mRNA levels were determined by Western blot and RT-qPCR. The cell proliferatin, migration and invasion were measured by CCK-8 and transwell assays. The protein interaction was detected by co-IP assay. The interaction between protein and DNA was performed by ChIP assay. The tumor growth in vivo was performed by xenograft tumor model. Results: SETD1A was overexpressed in OV and a predictor of poor prognosis. Overexpression of SETD1A augmented the abilities of cell proliferation, migration, and invasion in MRG1 and OVCAR5 cells. In comparison, SETD1A knockdown suppressed cell growth, migration, and invasion in SKOV3 and Caov3 cells. Specifically, SETD1A enhanced Notch signaling by promoting the expression of Notch target genes, such as Hes1, Hey1, Hey2, and Heyl. Mechanistically, SETD1A interacted with Notch1 and methylated H3K4me3 at Notch1 targets to enhance Notch signaling. In addition, restoration of Notch1 in SETD1A-knockdown OV cells recovered cell proliferation, migration and invasion, which was inhibited by SETD1A knockdown. Furthermore, reduction of SETD1A suppressed tumorigenesis in vivo. Conclusion: In conclusion, our results highlighted the key role of SETD1A in OV development and proved that SETD1A promotes OV development by enhancing Notch1 signaling, indicating that SETD1A may be a novel target for OV treatment.


  • Construction and comprehensive analysis of a lncRNA–mRNA interactive network to reveal a potential lncRNA for hepatic encephalopathy development

    by Chihao Zhang, Wei Ni, Yiming Zhu, Jiayun Lin, Hongjie Li, Zhifeng Zhao, Ke Wang, Haizhong Huo, Meng Luo

    Little is known about the role of lncRNA–mRNA regulatory relationships in hepatic encephalopathy (HE). Here, we aimed to construct the potential lncRNA and mRNA interactive network in forecasting HE development in patients with liver cirrhosis using different bioinformatic analysis method. Through analyses, we found that AL137857.1 had the most connections with other mRNAs and was deemed as a hub lncRNA. It was obviously upregulated in HE patients, which was also validated by another independent dataset. GO and KEGG analyses suggested that AL137857.1 was involved in microglial cell activation, phagocytosis, cytokine biosynthetic process, interleukin-6 production and tumor necrosis factor production. In vitro experiments suggested LPS could stimulate microglia to generate AL137857.1. In addition, we found that inhibition of AL137857.1 suppressed the expression of a series of inflammatory cytokines, including IL-1, IL-6, TNF-α, Cox2 and iNOS. Conversely, AL137857.1 over-expression induced a marked increase in these factors. Finally, AL137857.1 was demonstrated to be highly associated with the ability of microglial phagocytosis. Taken together, we have constructed a lncRNA–mRNA regulatory network associated with HE and explored the biological significance of mRNAs in the network, then discovered a novel lncRNA AL137857.1 in HE that might act as a potential regulator of the downstream inflammatory cytokines.